Thermo Fisher Partners with Singapore’s PRECISE-SG100K to Scale Proteomics in Population Health
Event summary
- Thermo Fisher Scientific is collaborating with Singapore’s PRECISE-SG100K study to advance population-scale proteomics, integrating its Olink® PEA platforms and Orbitrap Astral mass spectrometry systems.
- The partnership aims to leverage AI-driven analytics on high-quality proteomic data for earlier disease detection, prevention, and personalized care.
- Thermo Fisher’s technologies will be used alongside Seer’s Proteograph® Product Suite to enable scalable, high-sensitivity protein measurement across 100,000 participants in Singapore.
The big picture
This collaboration underscores the growing importance of proteomics in national health strategies, as biobanks increasingly rely on multi-omic platforms and AI to uncover complex biological patterns. Thermo Fisher’s involvement in multiple large-scale biobank initiatives highlights its strategic role in advancing precision medicine globally.
What we're watching
- Technology Integration
- How Thermo Fisher’s combined proteomics platforms will enhance reproducibility and regulatory-grade evidence generation in large-scale studies.
- Market Expansion
- Whether this collaboration positions Thermo Fisher as a leader in global biobank infrastructure development, following similar engagements with UK Biobank and FinnGen.
- Data Utilization
- The pace at which AI-driven proteomic data will translate into actionable insights for disease prevention and personalized care across diverse populations.
Related topics